The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.

Article Details

Citation

Copy to clipboard

Koo HL, Dupont HL, Huang DB

The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.

Ther Clin Risk Manag. 2009;5:841-8. Epub 2009 Nov 2.

PubMed ID

19898648 [ View in PubMed

]

Abstract

Travelers' diarrhea is a common illness among international travelers from developed to developing countries. Travelers' diarrhea is caused by ingestion of contaminated food and water. Bacteria are the primary cause of travelers' diarrhea. In most surveys, the most common diarrheal pathogen identified is enterotoxigenic Escherichia coli. There are several antimicrobial agents available for the treatment of travelers' diarrhea including rifaximin which is approved in the United States for the treatment of travelers' diarrhea due to noninvasive E. coli strains. In this review, we will review the most recent advances of rifaximin for the treatment and prevention of travelers' diarrhea, with regard to its pharmacokinetics, in vitro susceptibility profile, and efficacy and safety data from clinical trials.

DrugBank Data that Cites this Article

Drugs

Rifaximin

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Rifaximin	DNA-directed RNA polymerase subunit beta	Protein	Escherichia coli (strain K12)	Yes	Inhibitor	Details